NEW YORK (GenomeWeb News) – Certara said this week that it is working with the Critical Path Institute, C-Path, to create a physiologically-based pharmacokinetic model of the human lung using Certara's Simcyp Population-based simulator software that will be used to test new tuberculosis drugs.

According to the partners, the model will be useful for predicting the disposition of drugs within the lungs and the potential impact of disease progression on drug kinetics at different stages of TB infection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease.